INVESTOR RELATIONS

As featured in the media

* STOCKHEAD – HeraMED secures landmark commercial agreement with Joondalup Health Campus
* THEMARKERLAND – HeraMED (ASX:HMD) arranges tech pilot at Joondalup Health Campus
* THE SENTIMENT- High-touch, high-quality maternity care could soon become standard in major hospitals

Latest Announcements

* For additional information about share price and latest announcements please review HeraMED’s page on the ASX platform View Page

Notification regarding unquoted securities – HMD05/05/2022View
Notification regarding unquoted securities – HMD04/05/2022View
Outstanding Results Achieved in Second JHC Clinical Trial02/05/2022View
Cleansing Notice29/04/2022View
Application for quotation of securities – HMD29/04/2022View
Quarterly Activities & Cashflow Report29/04/2022View
Investor Presentation – April 202226/04/2022View
HMD-Pediatrix Virtual OB Pilot Shows Promising Results 19/04/2022View
Appendix 4G and Corporate Governance Statement29/03/2022View
Annual Report to shareholders29/03/2022View
Notification of cessation of securities – HMD01/03/2022View
Appendix 4E & Preliminary Final Report25/02/2022View
Notification of cessation of securities – HMD25/02/2022View
Cleansing Notice21/02/2022View
Application for quotation of securities – HMD21/02/2022View
Quarterly Activities & Cashflow Report30/01/2022View
Cleansing Notice28/01/2022View
Application for quotation of securities – HMD28/01/2022View
Reinstatement to Official Quotation21/01/2022View
JHC agrees to full commercial rollout of HeraCARE21/01/2022View
Suspension from Official Quotation20/01/2022View
Trading Halt18/01/2022View
Pause in Trading18/01/2022View
Results of Meeting20/12/2021View
Notification of cessation of securities – HMD10/12/2021View
Notification of cessation of securities – HMD10/12/2021View
Cleansing Notice09/12/2021View
Application for quotation of securities – HMD09/12/2021View
Change of Director’s Interest Notice x 307/12/2021View
Cleansing Notice07/12/2021View
Application for quotation of securities – HMD07/12/2021View
Cleansing Notice02/12/2021View
Application for quotation of securities – HMD02/12/2021View
Notice of General Meeting/Proxy Form18/11/2021View
Update on Placement Capacity15/11/2021View
Response to ASX Price Query15/11/2021View
Cleansing Notice29/09/2021View
Quarterly Activities & Cashflow Report29/09/2021View
Appendix 3G28/09/2021View
Proposed issue of securities – HMD18/09/2021View
$2.39 million raised via a Convertible Note18/09/2021View
Trading Halt14/09/2021View
Positive Interim Results US Paid Pilot & 2nd Site Confirmed13/09/2021View
HeraCARE Shortlisted for Government tender in Spain01/09/2021View
Appendix 4D and Half Year Report 27/08/2021View
Cleansing Prospectus16/08/2021View
Sheba Expands Pilot to include High-Risk Pregnancies02/08/2021View
Quarterly Activities & Cashflow Report29/07/2021View
Results of Meeting 23/07/2021View
Change of Registered Office19/07/2021View
Update – Notice of Extraordinary General Meeting19/07/2021View
HeraCARE paid pilot commences with US-based Obstetrix Group19/07/2021View
Application for quotation of securities – HMD14/07/2021View
Application for quotation of securities – HMD30/06/2021View
Notice of Extraordinary General Meeting/Proxy Form23/06/2021View
Notification regarding unquoted securities – HMD 15/06/2021View
Appendix 3G15/06/2021View
Results of Annual General Meeting31/05/2021View
Chairman’s letter to shareholders 31/05/2021View
Updated Investor Presentation and Webinar17/05/2021View
Pilot agreement signed with US leader Obstetrix Medical 13/05/2021View
Trading Halt11/05/2021View
Appendix 2A03/05/2021View
Notice of Annual General Meeting/Proxy Form29/04/2021View
Quarterly Activities & Cashflow Report28/04/2021View
HeraCARE commercial agreement with Joondalup Health Campus22/04/2021View
Trading Halt20/04/2021View
Appendix 4G and Corporate Governance Statement 29/03/2021View
Annual Report to shareholders29/03/2021View
JHC’s Study Published One of Most Cited Scientific Journals Link to journals Link to Poadcast 15/03/2021View
Appendix 4E & Preliminary Final Report 26/02/2021View
Becoming a substantial holder18/02/2021View
Appendix 2A & Cleansing Notice10/02/2021View
Israel’s Largest Healthcare Provider Begins Pilot Study08/02/2021View
Proposed issue of Securities – HMD04/02/2021View
Proposed issue of Securities – HMD04/02/2021View
Completion of AUD 2.3M Placement04/02/2021View
Trading Halt02/02/2021View
Quarterly Activities & Cashflow Report29/01/2021View
Hapvida Extends Subscription on new SaaS Terms26/01/2021View
Updated HeraMED Investor Update Conference Call17/12/2020View
HeraMED Investor Update Conference Call 17/12/2020View
Mayo Clinic approves Clinical Study of HeraBEAT 15/12/2020View
Partnership to Launch HeraCARE & HeraBEAT with Teleperinatal 15/12/2020View
Appendix 2A14/12/2020View
Release from escrow23/11/2020View
Partnership with eCare21 – Additional Information 16/11/2020View
Partnership with eCare21 & functional integration complet08/11/2020View
Quarterly Activities & Cashflow Report29/10/2020View
Amended Updated Investor Presentation21/10/2020View
Updated Investor Presentation21/10/2020View
HMD Clinical Study Results Conference Call08/10/2020View
Clinical & Functional Validation of HeraBEAT Achieved at JHC08/10/2020View
Partnership with Leading Virtual Care Platform eCare21 in US16/09/2020View
Appendix 2A07/09/2020View
Enrolment in Clinical Study at JHC Completed Ahead Schedule03/09/2020View
Appendix 4D and Half Year Report25/08/2020View
Proposed issue of Securities – HMD14/08/2020View
Proposed issue of Securities – HMD14/08/2020View
Appendix 2A11/08/2020View
Appendix 2A11/08/2020View
Cleansing Notice05/08/2020View
Proposed issue of Securities – HMD05/08/2020View
Successful Placement of SPP Shortfall05/08/2020View
Updated Quarterly Activities Report03/08/2020View
Change of Director’s Interest Notice03/08/2020View
Quarterly Activities & Cashflow Report29/07/2020View
Study Commenced & Recruitment Initiated – Joondalup Campus27/07/2020View
Change of Director’s Interest Notice23/07/2020View
Appendix 2A21/07/2020View
Reinstatement to Official Quotation21/07/2020View
Proposed issue of Securities – HMD21/07/2020View
Proposed issue of Securities – HMD21/07/2020View
Proposed issue of Securities – HMD21/07/2020View
HeraMED Extends its Collaboration with Mayo Clinic21/07/2020View
Suspension from Official Quotation20/07/2020View
Trading Halt16/07/2020View
Pause In Trading16/07/2020View
Results of Annual General Meeting14/07/2020View
Results of Share Purchase Plan Offer13/07/2020View
Final Approvals Received to Commence Clinical Study13/07/2020View
Update on HMD SPP Offer25/06/2020View
Becoming a substantial holder24/06/2020View
Appendix 2A and Cleansing Notice15/06/2020View
Letter to Shareholders regarding Notice of AGM12/06/2020View
Notice of Annual General Meeting/Proxy Form12/06/2020View
HMD SPP Offer Booklet and Application Form12/06/2020View
SPP Cleansing Notice12/06/2020View
Appendix 3B05/06/2020View
Company Presentation – June 202005/06/2020View
HMD Raises $2.32 Million and Launches SPP05/06/2020View
Trading Halt01/06/2020View
Agreement with Freeman Rd & PHI Group – Pilots in Australia20/05/2020View
Exclusive Agreement Executed with Australian Distributor08/05/2020View
Quarterly Activities and CashFlow Report01/05/2020View
New FDA Recommendations – Fetal & Maternal Monitoring27/04/2020View
Appendix 2A & Cleansing Notice17/04/2020View
US Market Entry Strategy Update07/04/2020View
US Market Strategy Presentation – April 202007/04/2020View
Appendix 4G and Corporate Governance Statement27/03/2020View
Annual Report to shareholders27/03/2020View
HMD Update & COVID-19 Opportunities Conference Call25/03/2020View
Company Update – COVID-19 To Accelerate Global Opportunities24/03/2020 View
HeraCARE Product Development Update02/03/2020 View
HeraCARE Presentation – March 202002/03/2020 View
Change of Company Secretary & Registered Address02/03/2020 View
Appendix 4E & Preliminary Final Report27/02/2020 View
Cleansing Notice20/02/2020 View
Appendix 2A19/02/2020 View
Proposed issue of Securities – HMD19/02/2020View
Results of General Meeting19/02/2020View
HeraBEAT Plus Clinical Trial Study Details17/02/2020View
Mayo Clinic clinical study to evaluate HeraBEAT Plus10/02/2020View
HeraMED appoints US General Manager of Operations03/02/2020View
December Quarter Activities Report and Appendix 4C30/01/2020View
Notice of Extraordinary General Meeting and Proxy Form20/01/2020View
HMD accesses unique pregnancy database to strengthen OrionAI20/01/2020View
Response to ASX Aware Query20/01/2020View
Update on Voluntary Escrow for Minor Vendor Options09/01/2020View
Cleansing Notice17/12/2019View
Appendix 3B17/12/2019View
Appendix 3B12/12/2019View
A$1.42m strategic placement completed to expedite US entry10/12/2019View
Trading Halt06/12/2019View
New CPT codes allow for potential reimbursement in USA04/12/2019View
2020 Company Outlook02/12/2019View
Change of Director’s Interest Notice – Tal Slonim28/11/2019View
Change of Director’s Interest Notice – David Groberman28/11/2019View
Appendix 3B and ASX Escrow Release28/11/2019View
Indian Hospital Group Cooperates with H-Cube and HeraMED25/11/2019View
Release of Securities from ASX Escrow Restriction20/11/2019View
HeraMED Receives FDA 510(k) Clearance for HeraBEAT Device18/11/2019View
Retraction of Statements – Next Tech Stock Article15/11/2019View
Trading Halt15/11/2019View
Pause in Trade15/11/2019View
Response to ASX Price and Volume Query14/11/2019View
Trading Halt14/11/2019View
Pause in Trading14/11/2019View
Hapvida Saude (Brazil) Trial Update07/11/2019View
Appendix 3B05/11/2019View
September Quarter Activities Report and Appendix 4C30/10/2019View
Market entry for HeraBEAT and HeraCARE Progresses in India25/10/2019View
HeraCARE – the digital era of pregnancy care14/10/2019View
Collaboration agreement secured with IntMED Software Ltd ME02/10/2019View
HMD passes first stage for Israel Innovation Authority Grant24/09/2019View
HeraMED and Mayo Clinic to co-develop a New Platform17/09/2019View
Global Distribution Progress Update04/09/2019View
Appendix 3B28/08/2019View
HeraMED Solutions Operational Across Multiple Hapvida Sites28/08/2019View
Appendix 4D and Half Year Report28/08/2019View
Correction to Appendix 4C14/08/2019View
HeraMED enters the German market with initial PO secured12/08/2019View
June Quarterly Activities Report & Appendix 4C31/07/2019View
HeraCARE Investor Presentation July 201922/07/2019View
HeraCARE PRO Integrated into Hapvidas Hospital Systems01/07/2019View
HeraBEAT Australian B2C launch underway19/06/2019View
Appendix 3B14/06/2019View
Appendix 3B06/06/2019View
Appendix 3B03/06/2019View
Release of Securities from Escrow31/05/2019View
Results of Annual General Meeting29/05/2019View
Annual General Meeting Venue Room Update24/05/2019View
Dr Friedman joins HeraMED advisory board20/05/2019View
HeraMED to launch HeraBEAT in Mexico15/05/2019View
Company Presentation May 201914/05/2019View
Release of Securities from Escrow09/05/2019View
HeraMED Expands European Distribution Network Clarification08/05/2019View
HeraMED Expands European Distribution Network08/05/2019View
HeraMED begins FDA Approval Process for HeraBEAT29/04/2019View
Notice of Annual General Meeting and Proxy Form26/04/2019View
March Quarterly Activity Report & Appendix 4C26/04/2019View
Meerkats Partners for HeraBEATs Australian B2C Launch16/04/2019View
HeraMED launches HeraBEAT in the United Kingdom11/04/2019View
Response to ASX Query – Annual Report as at 31/12/1808/04/2019View
Addendum to Annual Report05/04/2019View
Appendix 4G29/03/2019View
Annual Report29/03/2019View
Orion Artificial Intelligence Presentation26/03/2019View
Dr Arturo Weschler MD Appointed to Lead Orion AI Operations26/03/2019View
Quasar Manufacturing Agreement to Deliver Scale & Efficiency13/03/2019View
Appendix 4E & Preliminary Final Report28/02/2019View
Major Brazilian Health Care Group Places Initial Pilot Order14/02/2019View
December Quarterly Activity Report & Appendix 4C31/01/2019View
Australian Distribution Agreement for 9000 HeraBEAT Units14/01/2019View
December Investor Presentation19/12/2018View
Becoming a substantial holder – Holley Pharmaceutical Group19/12/2018View
HeraMED Completes Over-Subscribed $6 Million IPO12/12/2018View
Becoming a substantial holder – Tal Slonim11/12/2018View
Becoming a substantial holder – David Groberman11/12/2018View
Initial Director’s Interest Notice – Tal Slonim11/12/2018View
Initial Director’s Interest Notice – Ronald Weinberger11/12/2018View
Initial Director’s Interest Notice – Doron Birger11/12/2018View
Initial Director’s Interest Notice – David Hinton11/12/2018View
Initial Director’s Interest Notice – David Groberman11/12/2018View
Statement of Confirmations10/12/2018View
Updated Statement of Commitments10/12/2018View
Voluntary Escrow10/12/2018View
Restricted Securities10/12/2018View
Updated Pro Forma Statement of Financial Position10/12/2018View
Capital Structure10/12/2018View
Securities Trading Policy10/12/2018View
Hera Med Ltd. Half Yearly Accounts to 30 June 201810/12/2018View
Hera Med Ltd. 2016 and 2017 Full Year Accounts10/12/2018View
Supplementary Prospectus10/12/2018View
Prospectus10/12/2018View
Constitution10/12/2018View
Appendix 1A and Information Form and Checklist10/12/2018View
Top 20 Holders10/12/2018View
Distribution Schedule10/12/2018View
ASX Notice – Admission to Official List10/12/2018View